<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04301336</url>
  </required_header>
  <id_info>
    <org_study_id>Novel TTT of pedia VOC/SCA</org_study_id>
    <nct_id>NCT04301336</nct_id>
  </id_info>
  <brief_title>Different Treatment Modalities in the Management of the Painful Crisis in Pediatric Sickle- Cell Anemia</brief_title>
  <official_title>Comparative Effectiveness of the Different Treatment Modalities for Management of Vaso-occlusive Painful Crisis in Pediatric Sickle Cell Disease</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Beni-Suef University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Department of clinical pharmacy, faculty of pharmacy, Beni-suef univeristy</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Benisuef university hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University of Arizona</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>College of Pharmacy,Department of Pharmacy Practice,University of Arizona</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Maternity and Children Hospital, Makkah</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Beni-Suef University</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aim of the present study is comparing the effectiveness of different treatment regimens
      for investigating the therapeutic potential for each one in management of Vaso-occlusive pain
      in pediatric sickle cell disease. In addition, investigators apply the Cost-effectiveness
      analysis (CEA) as a form of economic analysis that compares the relative costs and outcomes
      (effects) for different treatment regimens on vaso-occlusive painful crisis.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      &quot;Sickle cell disease is an inherited blood disorder characterized by defective hemoglobin (a
      protein in red blood cells that carries oxygen to the tissues of the body).

      Sickle cell disease involves the red blood cells, or hemoglobin, and their ability to carry
      oxygen. Normal hemoglobin cells are smooth, round, and flexible, like the letter &quot;O,&quot; so they
      can move through the vessels in our bodies easily. Sickle cell hemoglobin cells are stiff and
      sticky and form into the shape of a sickle, or the letter &quot;C,&quot; when they lose their oxygen.
      These sickle cells tend to cluster together and cannot easily move through the blood vessels.
      The cluster causes a blockage in small arteries or capillaries and stops the movement of
      healthy, normal oxygen-carrying blood. This blockage is what causes the painful and damaging
      complications of sickle cell disease&quot;.

      &quot;Acute vaso-occlusive crisis (VOC) is a hallmark of sickle cell disease (SCD). Multiple
      complex pathophysiological processes can result in pain during a VOC. Despite significant
      improvements in the understanding and management of SCD, little progress has been made in the
      management of pain in SCD, although new treatments are being explored&quot;.

      The Painful Episodes:

      &quot;The day-to-day management of sickle cell disease often equates with the management of acute
      and chronic pain. Patients manage many painful events at home so that hospital visits
      underestimate the frequency of pain

      Acute painful episodes are the most commonly encountered vaso-occlusive events in patients of
      all ages. Presumed to be caused by sickle vaso-occlusion, pain often starts in young children
      as the hand-foot syndrome or dactylitis, a painful swelling of hands and feet due to
      inflammation of the metacarpal and metatarsal periosteum. Painful episodes, which last from
      hours to many days, usually occur with little warning and a clear precipitating event is not
      often found.
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">November 1, 2019</start_date>
  <completion_date type="Anticipated">November 2020</completion_date>
  <primary_completion_date type="Anticipated">October 2020</primary_completion_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Four experimental groups, one control group</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Care Provider)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>C-reactive protein mg/L</measure>
    <time_frame>10 months</time_frame>
    <description>C-reactive protein milligrams per deciliter</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Hematocrit %</measure>
    <time_frame>10 months</time_frame>
    <description>Hematocrit level in percentage value</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Fibrinogen mg/dl</measure>
    <time_frame>10 months</time_frame>
    <description>Fibrinogen concentration in milligrams per deciliter</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Total cholesterol Mg/dl</measure>
    <time_frame>10 months</time_frame>
    <description>Total cholesterol milligrams per deciliter</description>
  </primary_outcome>
  <primary_outcome>
    <measure>HDL cholesterol Mg/dl</measure>
    <time_frame>10 months</time_frame>
    <description>HDL cholesterol milligrams per deciliter</description>
  </primary_outcome>
  <primary_outcome>
    <measure>LDL cholesterol Mg/dl</measure>
    <time_frame>10 months</time_frame>
    <description>LDL cholesterol milligrams per deciliter</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Triglycerides Mg/dl</measure>
    <time_frame>10 months</time_frame>
    <description>Triglycerides milligrams per deciliter</description>
  </primary_outcome>
  <primary_outcome>
    <measure>leukocytes count μl</measure>
    <time_frame>10 months</time_frame>
    <description>leukocytes in microliter</description>
  </primary_outcome>
  <primary_outcome>
    <measure>hemoglobin (Hbg) g/dL</measure>
    <time_frame>10 months</time_frame>
    <description>hemoglobin (Hbg) gram/deciliter</description>
  </primary_outcome>
  <primary_outcome>
    <measure>White blood cells count</measure>
    <time_frame>10 months</time_frame>
    <description>White blood cells count in a cubic milliliter of blood</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Lactic acid dehydrogenase U/L</measure>
    <time_frame>10 months</time_frame>
    <description>Lactic acid dehydrogenase unit per litter</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Reticulocyte count %</measure>
    <time_frame>10 months</time_frame>
    <description>Reticulocyte count percentage</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Red blood cell (erythrocyte ) sedimentation rate mm/hr</measure>
    <time_frame>10 months</time_frame>
    <description>erythrocyte sedimentation rate in millimeters (mm) per one hour(hr)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>lymphocyte count µL</measure>
    <time_frame>10 months</time_frame>
    <description>lymphocyte count in 1 microliter (µL) of blood</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Granulocyte absolute count cells/microliter</measure>
    <time_frame>10 months</time_frame>
    <description>Granulocyte cells numbers in microliter</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Granulocytes,percentage (GR, pct)</measure>
    <time_frame>10 months</time_frame>
    <description>percentage of white blood cells with granules in percentage</description>
  </primary_outcome>
  <number_of_arms>5</number_of_arms>
  <enrollment type="Actual">350</enrollment>
  <condition>Vaso-occlusive Crisis</condition>
  <condition>Sickle Cell Disease</condition>
  <condition>Sickle Cell Anemia in Children</condition>
  <arm_group>
    <arm_group_label>Omega-3 experimental group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>50 patients from each participating hospital that will receive Omega-3 supplementation (300-400mg EPA &amp; 200-300mg DHA) per day for 8 consecutive months up to 10 months.
in addition to the experimental treatment, this group will receive the traditional treatment of hydroxyurea, Folic acid, pain killer plus regular blood transfusion with a dose de-escalation methods till efficacy of experimental treatment proved.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Vit-D experimental group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>50 patients from each participating hospital that will receive Vit-D medication (1500 IU to 3500 IU ) per day for 8 consecutive months up to 10 months.
in addition to the experimental treatment, this group will receive the traditional treatment of hydroxyurea, Folic acid, pain killer plus regular blood transfusion with a dose de-escalation methods till efficacy of experimental treatment proved.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Zinc supplements experimental group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>50 patients from each participating hospital that will receive Zinc supplements (15 mg to 50 mg ) per day for 8 consecutive months up to 10 months.
in addition to the experimental treatment, this group will receive the traditional treatment of hydroxyurea, Folic acid, pain killer plus regular blood transfusion with a dose de-escalation methods till efficacy of experimental treatment proved.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Statin experimental group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>50 patients from each participating hospital that will receive Simvastatin orally (20 mg to 40 mg ) per day for 8 consecutive months up to 10 months.
in addition to the experimental treatment, this group will receive the traditional treatment of hydroxyurea, Folic acid, pain killer plus regular blood transfusion with a dose de-escalation methods till efficacy of experimental treatment proved.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Ordinary hospital treatment group</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>50 patients from each participating hospital that will receive the ordinary treatment of Hydroxyurea (20 mg/kg/day) with monitoring blood count every 2 weeks maximum daily dose: (40 mg/kg/day) for 8 consecutive months up to 10 months.
in addition, Folic Acid dose of 0.5 to 1 mg daily for 3 to 4 weeks until definite hematologic response in addition, Morphine medication as a pain killer is administered, if Patient weight &lt;50 kg: Opioid naïve: Initial: 0.05 mg/kg/dose; usual maximum initial dose: 1 to 2 mg/dose.
This group received regular blood transfusion session.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Omega 3</intervention_name>
    <description>Omega-3 supplementation (300-400mg EPA &amp; 200-300mg DHA) per day for 8 consecutive months up to 10 months</description>
    <arm_group_label>Omega-3 experimental group</arm_group_label>
    <other_name>omega-3 supplementation capsules</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Vit D</intervention_name>
    <description>50 patients from each participating hospital that will receive Vit-D medication (1500 IU to 3500 IU ) per day for 8 consecutive months up to 10 months.
in addition to the experimental treatment, this group will receive the traditional treatment of hydroxyurea, Folic acid, pain killer plus regular blood transfusion with a dose de-escalation methods till efficacy of experimental treatment proved.</description>
    <arm_group_label>Vit-D experimental group</arm_group_label>
    <other_name>Vit-D medication oral drops</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Zinc sulfate</intervention_name>
    <description>50 patients from each participating hospital that will receive Zinc supplements (15 mg to 50 mg ) per day for 8 consecutive months up to 10 months.
in addition to the experimental treatment, this group will receive the traditional treatment of hydroxyurea, Folic acid, pain killer plus regular blood transfusion with a dose de-escalation methods till efficacy of experimental treatment proved.</description>
    <arm_group_label>Zinc supplements experimental group</arm_group_label>
    <other_name>Zinc tablet medication</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Statins (Cardiovascular Agents)</intervention_name>
    <description>50 patients from each participating hospital that will receive Simvastatin orally (20 mg to 40 mg ) per day for 8 consecutive months up to 10 months.
in addition to the experimental treatment, this group will receive the traditional treatment of hydroxyurea, Folic acid, pain killer plus regular blood transfusion with a dose de-escalation methods till efficacy of experimental treatment proved.</description>
    <arm_group_label>Statin experimental group</arm_group_label>
    <other_name>Simvastatin 20mg</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Hydroxy Urea</intervention_name>
    <description>50 patients from each participating hospital that will receive the ordinary treatment of Hydroxyurea (20 mg/kg/day) with monitoring blood count every 2 weeks maximum daily dose: (40 mg/kg/day) for 8 consecutive months up to 10 months.</description>
    <arm_group_label>Omega-3 experimental group</arm_group_label>
    <arm_group_label>Ordinary hospital treatment group</arm_group_label>
    <arm_group_label>Statin experimental group</arm_group_label>
    <arm_group_label>Vit-D experimental group</arm_group_label>
    <arm_group_label>Zinc supplements experimental group</arm_group_label>
    <other_name>Hydroxy Urea tablet medication 20mg/kg/day</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Folic Acid Supplementation</intervention_name>
    <description>Folic Acid dose of 0.5 to 1 mg daily for 3 to 4 weeks until definite hematologic response</description>
    <arm_group_label>Omega-3 experimental group</arm_group_label>
    <arm_group_label>Ordinary hospital treatment group</arm_group_label>
    <arm_group_label>Statin experimental group</arm_group_label>
    <arm_group_label>Vit-D experimental group</arm_group_label>
    <arm_group_label>Zinc supplements experimental group</arm_group_label>
    <other_name>Folic Acid tablet medication 1mg/day</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Morphine Sulfate</intervention_name>
    <description>Morphine medication as a pain killer is administered, if Patient weight &lt;50 kg: Opioid naïve: Initial: 0.05 mg/kg/dose; usual maximum initial dose: 1 to 2 mg/dose.</description>
    <arm_group_label>Omega-3 experimental group</arm_group_label>
    <arm_group_label>Ordinary hospital treatment group</arm_group_label>
    <arm_group_label>Statin experimental group</arm_group_label>
    <arm_group_label>Vit-D experimental group</arm_group_label>
    <arm_group_label>Zinc supplements experimental group</arm_group_label>
    <other_name>Morphine Sulfate intra venous medication</other_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>blood transfusion session</intervention_name>
    <description>Regular blood transfusion session based on patient hematological profile starts from one session every 2 weeks.</description>
    <arm_group_label>Omega-3 experimental group</arm_group_label>
    <arm_group_label>Ordinary hospital treatment group</arm_group_label>
    <arm_group_label>Statin experimental group</arm_group_label>
    <arm_group_label>Vit-D experimental group</arm_group_label>
    <arm_group_label>Zinc supplements experimental group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        Any case with the full manifestation of sickle cell disease accompanied by acute painful
        crisis aged from 5-15 years old.

        Exclusion Criteria:

          1. The presence of any other chronic illness.

          2. Patient age&gt;18 years old or &lt; 3 years old.

          3. Patients with hepatic diseases including cholestasis hepatic encephalopathy and
             jaundice.

          4. Patients with renal impairment

          5. Diabetic patients
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>5 Years</minimum_age>
    <maximum_age>15 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>John E. Murphy [Professor of Pharmacy Practice and Science], PharmD</last_name>
    <role>Study Director</role>
    <affiliation>University of Arizona, College of Pharmacy</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Mohamed H Meabad [Prof of Pediatrics], M.D</last_name>
    <role>Study Director</role>
    <affiliation>Beni-Suef University, Faculty of medicine</affiliation>
  </overall_official>
  <overall_official>
    <last_name>AHMED A ALBERRY [Assistant prof of clinical pharmacology], M.D</last_name>
    <role>Study Director</role>
    <affiliation>Beni-Suef University, Faculty of medicine</affiliation>
  </overall_official>
  <overall_official>
    <last_name>RAGHDA R SAYED [Lecturer of Clinical Pharmacy, Ph.D.</last_name>
    <role>Study Director</role>
    <affiliation>Beni-Suef University, Faculty of Pharmacy</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Shaimaa M Nashat Sayed Abdelhalim, Ph.D Student</last_name>
    <role>Principal Investigator</role>
    <affiliation>Beni-Suef University, Faculty of Pharmacy</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Ahmed F Mahmoud Hussein, MS.c</last_name>
    <role>Study Director</role>
    <affiliation>Beni-Suef Health insurance hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Faculty of medicine, Beni-suef univeristy - Beni-Seuf university hospital</name>
      <address>
        <city>Banī Suwayf</city>
        <country>Egypt</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Faculty of Pharmacy, Beni-Suef university</name>
      <address>
        <city>Banī Suwayf</city>
        <country>Egypt</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Health insurance hospital</name>
      <address>
        <city>Banī Suwayf</city>
        <country>Egypt</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Maternity and Children hospital</name>
      <address>
        <city>Mecca</city>
        <country>Saudi Arabia</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Egypt</country>
    <country>Saudi Arabia</country>
  </location_countries>
  <verification_date>July 2020</verification_date>
  <study_first_submitted>March 6, 2020</study_first_submitted>
  <study_first_submitted_qc>March 6, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">March 10, 2020</study_first_posted>
  <last_update_submitted>July 10, 2020</last_update_submitted>
  <last_update_submitted_qc>July 10, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">July 14, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Beni-Suef University</investigator_affiliation>
    <investigator_full_name>SHAIMAA MAHMOUD NASHAT SHAYED ABDELHALIM</investigator_full_name>
    <investigator_title>Dr.Shaimaa Mahmoud Nashat Sayed Abdelhalim, Ph.D. Researcher and Principal Investigator</investigator_title>
  </responsible_party>
  <keyword>omega3</keyword>
  <keyword>Vaso-occlusive painful crisis</keyword>
  <keyword>Pediatric sickle cell anemia</keyword>
  <keyword>comparative effective analysis in VOC</keyword>
  <keyword>Anti-inflammatory effect of Vit-D</keyword>
  <keyword>Anti-hemolytic effect of Vit-D</keyword>
  <keyword>Anti-hyperlipidemia of Vit-D</keyword>
  <keyword>effect of omega-3 on blood rheology</keyword>
  <keyword>effect of omega-3 on blood viscosity</keyword>
  <keyword>Antiaggregation effect of omega-3</keyword>
  <keyword>Anti-inflammatory effect of statins</keyword>
  <keyword>Anti-inflammatory effect of zinc supplements</keyword>
  <keyword>effect of zinc supplements on blood viscosity</keyword>
  <keyword>effect of zinc supplements on blood rheology</keyword>
  <keyword>Antiaggregation effect of zinc supplements</keyword>
  <keyword>pediatric sickle cell disease</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Anemia</mesh_term>
    <mesh_term>Anemia, Sickle Cell</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Folic Acid</mesh_term>
    <mesh_term>Vitamin B Complex</mesh_term>
    <mesh_term>Zinc</mesh_term>
    <mesh_term>Hydroxyurea</mesh_term>
    <mesh_term>Morphine</mesh_term>
    <mesh_term>Zinc Sulfate</mesh_term>
    <mesh_term>Simvastatin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

